Taginostat, a new quinolone-based HDAC6 inhibitor, promotes apoptosis of chronic lymphocytic leukemia cells in vitro and in vivo by activating STAT4
A new drug restores cancer-fighting pathways in leukemia cells, showing promise in laboratory models as a potential future treatment option.
Taginostat is a structurally novel quinolone-based HDAC6 inhibitor that restores the STAT4-p66Shc apoptotic pathway characteristically suppressed in CLL, validated in primary patient cells and xenograft models. The mechanistic novelty of targeting the STAT4/p66Shc axis positions Taginostat as a candidate for clinical translation in CLL, though only preclinical data are currently available.
What the study was
- Study design
- Preclinical mechanistic study with primary CLL patient cells and xenograft in vivo model
- Population
- Primary CLL patient cells (in vitro) and CLL xenograft mouse model (in vivo)
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Apoptosis
Why it surfaced
Novel HDAC6 inhibitor with unique STAT4/p66Shc mechanism for CLL apoptosis; primary patient cell + xenograft data; high mechanistic novelty warrants monitoring for Phase I development.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.